Systemic Inflammatory Biomarkers in Ovarian Cancer

Bakirkoy Dr. Sadi Konuk Training and Research Hospital

Status: Completed

Conditions: Ovarian Cancer

Treatments: Other: group without complications; Other: group with complications

Study type: Observational

Funder types: Other

Identifiers

NCT06629831

2024-59

Details and patient eligibility

About

In cancer patients, prognostic markers are needed to improve the management and clinical course of both the cancer itself and surgery therefor. Elevated systemic inflammatory markers are associated with morbidity and mortality in most cancer types. In this study, the investigators aimed to determine the prognostic value of inflammatory markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) in patients undergoing cytoreductive surgery for ovarian cancer.

Full description

Major gynaecological cancer surgery is a procedure with high complication rates and mortality risk due to both the patient' s old age and comorbidities and the extent of the surgery. Among such surgeries, ovarian cancer-related surgery has the highest mortality rate. Despite advances in early drug therapy and improvements in the cytotoxicity of drugs, ovarian cancer is frequently diagnosed at advanced stages, which further increases morbidity and mortality rates. Although many years have passed, the prognostic role of cytoreductive surgery on survival in ovarian cancers continues to be important. Predicting postoperative outcomes in these surgeries may reduce the length of hospital stay, need for stay in the intensive care unit, complications, and mortality. Therefore, the role of systemic inflammatory biomarkers needs to be comprehensively investigated to understand the carcinogenic mechanisms better.

For this purpose, the investigators planned to evaluate the prognostic effect of systemic inflammatory biomarkers on postoperative complications.

Enrollment: 90 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years of age

Exclusion criteria

• Patients with acute or inflammatory diseases
• Patients with hematological malignancies
• Patients with autoimmune diseases patients who underwent intraoperative hyperchemotherapy (HIPEC)

Trial design

90 participants in 1 patient group

Patients undergoing cytoreduction surgery for ovarian cancer

Description:

Patients undergoing cytoreduction surgery for ovarian cancer

Treatment:

Other: group with complications

Other: group without complications